Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASTLE: MB-CART19.1 CAR-T cells in systemic B cell-mediated autoimmune disease
2024-516819-24-00Phase 2Authorised
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- May 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of zorpocabtagene autoleucel in systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and Autoimmune Myopathies (3 arms), sponsored by Miltenyi Biomedicine GmbH. Primary endpoint: Incidence and severity of cytokine release syndrome and ICANS. Planned start May 2023; status: authorised.
02
Drugs
zorpocabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)Autoimmune Myopathies
Beyond the preview
Go deeper on 2024-516819-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516819-24-00.